The Mechanism of T Cells in the Microenvironment of Triple Negative Breast Cancer and the Application Potential of Immunotherapy
DOI:
https://doi.org/10.62051/9kwtbj74Keywords:
Triple-negative breast cancer; T cell; specific antibody; immunotherapy; combined therapy.Abstract
Triple negative BC (TNBC) is a malignant tumor with high invasion, high incidence rate and poor prognosis. The mechanism of T cells in its microenvironment and the potential application of immunotherapy have become the focus of current research. Research has shown that the tumor microenvironment of TNBC is highly heterogeneous, and T cells, as core members of the immune system, play a crucial role in the anti-tumor process by recognizing and clearing tumor cells. However, T cell activity is often suppressed by ICs such as PD-1/PD-L1, leading to tumor immune escape. With the development of single-cell RNA sequencing technology, there is a deeper understanding of the functional status of T cells in the TNBC microenvironment. Meanwhile, IC inhibitors (ICIs) and adoptive cell immunotherapy have shown significant potential in the treatment of TNBC. For example, PD-1 inhibitors combined with chemotherapy significantly prolonged the lifespan of TNBC patients. The results of this study reveal that the activation of T cells in the TNBC microenvironment is closely related to tumor prognosis, and immunotherapy can improve the therapeutic effect of TNBC patients by regulating T cell activity. The research significance lies in providing new strategies for the precise treatment of TNBC, especially the broad application prospects of immunotherapy. In the future outlook, with the deepening understanding of the molecular mechanism and immune microenvironment of TNBC, as well as the development of new immunotherapy drugs, the prognosis of TNBC patients is expected to further improve, achieving more personalized and effective treatment plans.
Downloads
References
[1] Zhang X, Ge X, Jiang T, Yang R, Li S. Research progress on immunotherapy in triple negative breast cancer (Review). International Journal of Oncology, 2022, 61(2): 95.
[2] Zhang JH, Zhang JY, Wang L. Research progress in Chinese and Western medicine treatments for triple-negative breast cancer. Western Journal of Traditional Chinese Medicine, 2024, 37(04): 91-96.
[3] Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunology, Immunotherapy, 2021, 70(3): 607-617.
[4] Vito A, Rathmann S, Mercanti N, El-Sayes N, Mossman K, Valliant J. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22(9): 4843.
[5] Hong J, Chen XS, Shen KW. Current status and prospects of immunotherapy for breast cancer. Tumor, 2013, 33(12): 1125-1129.
[6] Lin LF, Chen YH, Liu S, Zhang L, Xie T. Application of radiomics in molecular subtyping and tumor microenvironment research of breast cancer. Journal of Guangdong Medical University, 2024, 42(2): 209-213.
[7] Huang QX, Chen TW. Advances in research on tumor immune suppression mechanisms in triple-negative breast cancer. Guangdong Medical Journal, 2024, 45(3): 391-396.
[8] Gong C, Lin Q, Song EW. Mechanisms of tumor immunotherapy and progress in breast cancer immunotherapy. Chinese Journal of Clinical Physicians (Electronic Edition), 2020, 14(11): 857-861.
[9] Wang XF, Zhang Q, Li XY. The role of regulatory T cells in breast cancer immunotherapy. Chinese Journal of Breast Diseases (Electronic Edition), 2017, 11(1): 47-49.
[10] Li XY, Li YP, Tan ZQ. Research progress on the application of immunotherapy in clinical treatment of breast cancer. Journal of Guangxi Medical University, 2023, 40(05): 891-898.
[11] He LH, Zhu XZ, Jiang YZ. Research progress on immunotherapy for triple-negative breast cancer. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(08): 842-853.
[12] Zhang HS, Wu JL, Li Y, Liu Y, Wang Z. Research progress on immune checkpoints and their inhibitors in breast cancer. Cancer Progress, 2023, 21(5): 481-485, 516.
[13] Patel KK, Hassan D, Nair S, Tejovath S, Kahlon SS, Peddemul A, Sikandar R, Mostafa JA. Role of immunotherapy in the treatment of triple-negative breast cancer: A literature review. Cureus, 2022, 14(11): e31729.
[14] Wang XF, Zhang Q, Li XY. The role of regulatory T cells in breast cancer immunotherapy. Chinese Journal of Breast Diseases (Electronic Edition), 2017, 11(1): 47-49.
[15] Feng LF, Zhang SW. Preventing cancer cell metastasis: "killer" T cells have "two hands." China Science Daily.
[16] Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Advances in immunotherapy for triple-negative breast cancer. Molecular Cancer, 2023, 22(1): 145.
[17] Jiang N. Advances in adoptive cell immunotherapy for breast cancer. Chinese Journal of Tumor Biotherapy, 2022, 29(6): 571-579.
[18] Mi ZW, Yang HJ, Xu J. Research progress on ROR1 CAR-T therapy in tumor immunotherapy. Journal of Medical Research, 2023, 52(08): 9-13.
[19] Wu QH, Yang YH, Zhao K, Chen L. Research progress on immunotherapy for triple-negative breast cancer. Cancer Progress, 2022, 20(22): 2276-2280, 2288.
[20] Zhao M. Efficacy and antitumor immune mechanisms of oncolytic virus OVH in treating triple-negative breast cancer. Xiamen University, 2022.
[21] Ma HY, Wang X. Research progress on oncolytic viruses in breast cancer treatment. Chinese Journal of Clinical Oncology, 2020, 47(16): 847-850.
[22] Xu C, Zhang X, Li Z. Clinical value of cytokines IL-6, TNF-α, and circulating tumor cells in prognosis monitoring of breast cancer. Clinical Laboratory Journal (Electronic Edition), 2020, 9(01): 8-9.
[23] Li HB, Xu YH. Application value of cytokines IL-6 and TNF-α in neoadjuvant therapy of breast cancer. Journal of Jilin Medical College: 1-4.
[24] Yang K, Zeng TY, Yin YM. Mechanisms and application progress of tumor immune biomarkers in breast cancer immunotherapy. Pharmaceutical Progress, 2024, 48(02): 85-95.
[25] Li HL, Zhang YL, Huang ZJ. The relationship between triple-negative breast cancer treatment and MYC. Xinjiang Medical Journal, 2024, 54(03): 338-342.
[26] Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clinical Cancer Research, 2018, 24(3): 511-520.
[27] Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Research, 2019, 8: F1000 Faculty Rev-1342.
[28] Marra A, Viale G, Curigliano G. Recent advances in triple-negative breast cancer: the immunotherapy era. BMC Medicine, 2019, 17(1): 90.
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







